4D pharma presents update on oncology program 4D pharma presents update on oncology program Enrollment progressing well for both expanded Part B of MRx0518 and Keytruda combination study, and pancreatic cancer study Further analysis of biomarker data in ongoing MRx0518 neoadjuvant monotherapy study
Leeds, UK – February 3, 2021 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.
“4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. This clinical and development progress has been achieved in spite of the headwinds of COVID-19,” said Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma. “As 4D pharma extends its leading position in this exciting and rapidly maturing field, we see the next 12 months as being instrumental for the space. We look forward to generating more clinical data from our ongoing studies of MRx0518 in multiple different tumor types and treatment settings. This will support 4D pharma’s continued productive engagement with regulatory authorities to develop the clinical strategy to bring this novel therapeutic to patients suffering from a range of cancers.”